Welcome to our dedicated page for RKLY news (Ticker: RKLY), a resource for investors and traders seeking the latest updates and insights on RKLY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RKLY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RKLY's position in the market.
Rockley Photonics Holdings Limited (NYSE: RKLY) has secured £12.9 million ($15.5 million) in R&D tax credits from the UK government for fiscal 2020. The company has filed its fiscal 2021 R&D tax credit application and plans to file for fiscal 2022 in 2023. Established in 2013, Rockley focuses on silicon photonics-based biosensing solutions aimed at a variety of biomarkers, positioning itself for advancements in mobile health monitoring.
Rockley Photonics Holdings Limited (NYSE: RKLY) announced receiving a notice from the NYSE on December 9, 2022, indicating non-compliance with listing standards due to an average market capitalization and stockholders’ equity below $50 million. While the notice has no immediate impact on its listing, Rockley will add a ‘.BC’ designation to its ticker symbol until compliance is regained. The company has 45 days to submit a compliance plan and aims to regain compliance within 18 months. Failure to comply could lead to delisting.
Rockley Photonics (NYSE: RKLY) announces a significant management restructuring aimed at fostering growth. Richard A. Meier steps in as president and CEO, while Andrew Rickman transitions to executive chairman after nine years as CEO. Chad Becker is now the interim CFO. The changes are designed to align the leadership with the company’s strategic priorities as it seeks to advance its silicon photonics-based biosensing solutions. Dr. Caroline Brown has left the board, with Dr. Nicolaus Henke appointed to the audit committee.
Rockley Photonics Holdings Limited (NYSE: RKLY) announced that Dr. Andrew Rickman, OBE, will participate in the Commonwealth Trade and Investment Summit 2022. He will join a panel discussion titled Global Pandemic Preparedness alongside key figures including Dr. Tedros Adhanom Ghebreyesus from WHO. The discussion will address the Covid-19 pandemic's impact and future health strategies. A live webcast will be available on Rockley's investor relations page, with a replay expected post-summit.
Rockley Photonics has achieved a significant milestone by demonstrating its silicon photonics electro-absorption modulator technology at 4 Kelvin, allowing ultra-sensitive image capture in low-light conditions and at longer distances. In collaboration with UC Santa Barbara, this advancement shows minimal performance degradation at cryogenic temperatures. This innovation promises smaller, lighter devices with reduced power consumption and cost across various applications, including infrared cameras and quantum computing interconnects.
Rockley Photonics Holdings Limited (NYSE: RKLY), a medical technology company specializing in silicon photonics-based biosensing solutions, announced its participation in two upcoming investor conferences:
- Bernstein 2nd Annual CGM Disruptors Conference on November 18, 2022, at 11:05 a.m. ET.
- BTIG Digital Health Forum Panel on November 21, 2022, at 11:00 a.m. ET.
Live webcasts will be available on the company’s investor relations page.
Rockley Photonics Holdings Limited (NYSE: RKLY) reported its Q3 2022 financial results, revealing a revenue of $0.6 million, down from $1.8 million in Q3 2021. The company recorded a net income of $12.0 million, attributed to fair value adjustments. Cash burn reduction strategies included headcount cuts and operational cost savings. The firm raised $90.6 million through a private placement to extend its financial runway. Key advancements included a successful human study showing promising blood pressure tracking and the unveiling of a next-generation laser chip, paving the way for further product innovations.
Rockley Photonics (NYSE: RKLY) will announce its third quarter 2022 financial results after market close on November 9, 2022. A conference call will follow at 5:00 p.m. ET to discuss the results and business outlook. Investors can join the call by dialing 877-407-0832 in the U.S. or +1 201-689-8433 internationally, with an option for a live webcast available on the company’s investor relations page.
Rockley builds photonics-based health monitoring solutions, aiming to transform multiple industries.
Rockley Photonics (NYSE: RKLY) has announced a financing agreement to raise approximately
Rockley Photonics Holdings Limited (NYSE: RKLY) announced on October 18, 2022, that it received a notice from the NYSE for non-compliance with its listing standards, specifically regarding a minimum average closing price of $1.00 per share over a 30-day trading period. The notice does not lead to immediate delisting but assigns a designation of '.BC' to the ticker symbol. Rockley has six months to regain compliance and is considering options such as a reverse stock split, subject to shareholder approval.
FAQ
What is the market cap of RKLY (RKLY)?
